Technology Bundle ID
TAB-3584

Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration

Applications
Linked ID
E-038-2021-0
Lead Inventors
David Eveleth (Trefoil Therapeutics, INC)
Co-Inventors
Asaf Alimardanov (NCATS)
Gautam Mitra (NCI)
Hui Fang Dong (NCI)
Trevor Broadt (NCI)
Vinay Vyas (NCI)
ICs
This technology includes the use of a novel formulation for an engineered version of Fibroblast Growth Factor 1 (FGF1), TTHX1114, that can be used to accelerate regeneration of the corneal endothelium after surgical lesions. FGFs are well-established regulators of migration and proliferation of corneal endothelial cells (CECs).
Commercial Applications
The engineered FGF1, TTHX1114, is currently being commercialized.
Competitive Advantages
Fibroblast growth factors 1 and 2 are currently used to accelerate healing in ocular surface wounds. These FGFs have three cystine residues that can lead to inactivation of the factor. The formulations in this technology remove these residues and result in the stable preservation of a functionally active recombinant FGF-1 (TTHX1114).

Request More Info

Licensing Contact: